Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.

Trial Details

NCT ID
NCT05188170
Phase
PHASE1
Sponsor
Stanford University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Niclosamide
Locations (sample)
  • Palo Alto, California, United States|37.44188,-122.14302

Key Eligibility Criteria

  • 1\. Prior morphologically-confirmed diagnosis of AML based on WHO Criteria 2. Has previously failed all available and suitable therapies for AML. D…
  • 5% blasts in the peripheral blood (confirmed by flow cytometry, cytogenetics or FISH), ≥ 1% MRD
  • \+ by flow cytometry, FISH, PCR or NGS, and not attributable to another cause (EXCEPTION: subjects with frank disease progression in the face of tr…
  • , calculated per the Mostellar formula 5. Must be able to tolerate po or ng medications. 6. Performance status: Subject ≤ 16 years old: Lansky ≥ 50…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →